Spark Biomedical, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial
- Conditions
- Heavy Menstrual Bleeding
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Spark Biomedical, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06814028
- Locations
- 🇺🇸
Five Liters - DECENTRALIZED STUDY, Dallas, Texas, United States
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
- Conditions
- Opioid Use DisorderOpioid Withdrawal
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Spark Biomedical, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06487533
- Locations
- 🇺🇸
Hazelden Betty Ford Foundation, Center City, Minnesota, United States
🇺🇸Battelle Memorial Institute, Columbus, Ohio, United States
Effect of Transcutaneous Auricular Neurostimulation on Cognitive Performance in a Laboratory Model of Acute Stress Reaction
- Conditions
- Acute Stress ReactionCognitive Performance
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Spark Biomedical, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06390267
- Locations
- 🇺🇸
Battelle Memorial Institute, Columbus, Ohio, United States
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
- Conditions
- Opioid Use DisorderRelapse
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Spark Biomedical, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05591703
- Locations
- 🇺🇸
Betty Ford Foundation, Rancho Mirage, California, United States
🇺🇸Hazelden Betty Ford Foundation, Plymouth, Minnesota, United States
Neurostimulation to Improve NOWS Outcomes
- Conditions
- Neonatal Abstinence SyndromeNeonatal Opioid Withdrawal Syndrome
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Spark Biomedical, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05129020
- Locations
- 🇺🇸
Medical University of South Carolina - Shawn Jenkins Children's Hospital, Charleston, South Carolina, United States
🇺🇸UT Southwestern Medical Center / Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
- Prev
- 1
- 2
- Next